In the case of the clinical trial NCT02520011145, demonstrable MCL-1 dependence in AML, as determined by mitochondrial profiling, was used to identify eligible patients, although this trial was later terminated due to slow enrollment. Here, MCL1 is linked to acute myeloid leukemia.